How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.


MMPACE- A novel screening assay for MMP inhibitors

Organization name

PVA Saarland



A wide range of human diseases such as diabetes mellitus typ I and autoimmune diseases like rheumatoid arthritis (RA) or multiple sclerosis (MS) go along with malfunctions in the regulation of matrix metalloproteinases, especially MMP-2 and MMP-9. The development and validation of novel inhibitors for MMP´s is often hampered by high costs of MMP production and purification from human tumor cells or fibroblasts and the necessity for subsequent in vitro activation steps by per se toxic anorganic compounds.


An innovative cell based MMP bioassay was invented, enabling high through-put screening of novel MMP inhibitors. The method is based on the heterologous expression and immobilization of biologically active forms of human MMP-2 and MMP-9 on the cell surface of the yeast Pichia pastoris via a novel, highly efficient cell surface display system. Yeast cells modified in this way can either be provided as fresh cells or freeze-dried, enabling their direct use in MMP inhibitor screenings.


  • Easy production with a GRAS status microorganism;
  • Less expensive production of the MMPace cells by fed-batch fermentation in a bioreactor;
  • No cost intensive purification procedures;
  • No environmentally harmful activation steps;
  • As easy to use as dissolved enzymes.


  • Bioassay for high through-put screening of novel MMP inhibitors.

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.


latest entries